Genstruct Appoints Douglas A. Lauffenburger, Ph.D., To Board of Directors
Tuesday, February 24, 2004, 9:00 am ET CAMBRIDGE MA – Genstruct Inc., a biopharmaceutical company that is leading the effort to solve complex biological problems using knowledge modeling and logical simulation, today announced the appointment of Douglas A. Lauffenburger, Ph.D., to its Board of Directors.
"I am thrilled to welcome to our board one of the world's leading scientists and visionaries in the field of computational systems biology," said Keith O. Elliston, Ph.D., President and CEO of Genstruct. "Dr. Lauffenburger is a world-renowned thought leader in the analysis of complex biological systems, and has broad experience in applying computer-assisted approaches to drug discovery. His participation at the Board of Directors level, and as a scientific advisor, will further enhance our ability to establish Molecular Epistemics as the standard knowledge-driven approach to drug discovery."
"This is a company that is pioneering a totally new approach to drug discovery; one that applies logical modeling and reasoning to the identification of drug mechanisms, disease mechanisms and biomarkers," said Dr. Lauffenburger. "I am extremely excited to be joining the Board of Genstruct, and look forward to working with the board and management team to cement Genstruct's leadership in the field of knowledge-driven drug discovery."
Douglas A. Lauffenburger is the Director of the Biological Engineering Division and Uncas & Helen Whitaker Professor of Biological Engineering, Chemical Engineering and Biology at the Massachusetts Institute of Technology (MIT). He is also a Member of the Center for Cancer Research, Center for Biomedical Engineering, and Biotechnology Process Engineering Center at MIT. He serves as Director on the Executive Committee of the MIT Computational & Systems Biology Initiative. Dr. Lauffenburger has served as a consultant or scientific advisory board member for Astra-Zeneca, CellPro, Entelos, Insert Therapeutics, Johnson & Johnson, Pfizer, SyStemix, the Burroughs-Wellcome Foundation, and the Whitaker Foundation.
Genstruct is a biopharmaceutical company that is leading the effort to solve complex biological problems using knowledge modeling and logical simulation (reasoning). Genstruct provides on-demand research capabilities to leading pharmaceutical companies in the pre-clinical and clinical settings. Genstruct's knowledge-based capabilities support the accurate profiling of candidate compounds for mechanisms of action, evaluate animal models for predictive efficacy and assist in patient stratification through biomarker identification. The Company also deploys its biological knowledge models for focused internal discovery in the areas of oncology, metabolic disorder, and inflammation.
For additional information regarding this announcement, please contact:
Director Strategic Marketing, Genstruct Inc.